Johnson & Johnson (NYSE:JNJ) had its price objective hoisted by stock analysts at Credit Suisse Group from $152.00 to $156.00 in a research note issued to investors on Thursday, BenzingaRatingsTable reports. The firm currently has an “outperform” rating on the stock. Credit Suisse Group’s price target would suggest a potential upside of 12.70% from the stock’s previous close.
Other analysts have also issued reports about the company. Zacks Investment Research raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $155.00 target price on the stock in a report on Wednesday, March 27th. Morgan Stanley increased their target price on Johnson & Johnson from $134.00 to $145.00 and gave the stock an “equal weight” rating in a report on Wednesday, April 17th. Barclays reissued an “equal weight” rating and set a $135.00 target price (down from $137.00) on shares of Johnson & Johnson in a report on Wednesday, January 23rd. Citigroup increased their target price on Johnson & Johnson from $139.00 to $147.00 and gave the stock a “neutral” rating in a report on Monday, February 25th. Finally, Wells Fargo & Co reissued an “outperform” rating and set a $157.00 target price (up from $152.00) on shares of Johnson & Johnson in a report on Monday, May 6th. Five research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $147.30.
Shares of JNJ traded up $1.60 during trading hours on Thursday, hitting $138.42. 1,732,452 shares of the company were exchanged, compared to its average volume of 6,696,763. The firm has a market cap of $368.09 billion, a P/E ratio of 16.92, a price-to-earnings-growth ratio of 2.37 and a beta of 0.67. Johnson & Johnson has a fifty-two week low of $118.62 and a fifty-two week high of $148.99. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.13 and a current ratio of 1.44.
Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, April 16th. The company reported $2.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.03 by $0.07. The company had revenue of $20.02 billion for the quarter, compared to analyst estimates of $19.55 billion. Johnson & Johnson had a return on equity of 36.29% and a net margin of 17.99%. Johnson & Johnson’s quarterly revenue was up .1% on a year-over-year basis. During the same period in the prior year, the firm posted $2.06 EPS. On average, research analysts predict that Johnson & Johnson will post 8.6 earnings per share for the current fiscal year.
A number of large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its stake in shares of Johnson & Johnson by 1.5% during the third quarter. Vanguard Group Inc. now owns 213,433,449 shares of the company’s stock valued at $29,490,100,000 after purchasing an additional 3,235,861 shares in the last quarter. Vanguard Group Inc boosted its stake in shares of Johnson & Johnson by 1.5% during the third quarter. Vanguard Group Inc now owns 213,433,449 shares of the company’s stock valued at $29,490,100,000 after purchasing an additional 3,235,861 shares in the last quarter. BlackRock Inc. boosted its stake in shares of Johnson & Johnson by 3.3% during the first quarter. BlackRock Inc. now owns 188,893,693 shares of the company’s stock valued at $26,405,453,000 after purchasing an additional 5,990,349 shares in the last quarter. Oregon Public Employees Retirement Fund boosted its stake in shares of Johnson & Johnson by 11,576.1% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 74,757,633 shares of the company’s stock valued at $579,000 after purchasing an additional 74,117,373 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of Johnson & Johnson by 8.2% during the fourth quarter. Geode Capital Management LLC now owns 36,364,874 shares of the company’s stock valued at $4,685,372,000 after purchasing an additional 2,741,351 shares in the last quarter. 66.91% of the stock is currently owned by institutional investors and hedge funds.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Featured Article: Understanding Compound Annual Growth Rate (CAGR)
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.